Close Menu

NEW YORK — Duke-National University of Singapore (NUS) Medical School, GenScript Biotech, and Singapore's Agency for Science, Technology and Research (A*STAR) said on Friday that they have partnered on the development and manufacture of a novel SARS-CoV-2 serology test.

The cPass SARS-CoV-2 Surrogate Virus Neutralization Test is designed to detect circulating neutralizing antibodies against the virus that block the interaction between the receptor binding domain of the viral spike glycoprotein and the ACE2 cell surface receptor.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.